Yüklüyor......
Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital
Background: Apixaban, a direct factor Xa inhibitor, is approved by the US Food and Drug Administration (FDA) for prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Apixaban’s compelling safety and efficacy data, combined with minimal laboratory monitoring, make it an attr...
Kaydedildi:
| Yayımlandı: | J Pharm Technol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998530/ https://ncbi.nlm.nih.gov/pubmed/34860985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/8755122517706423 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|